CMPS trades within ±12% of $11.39 through September 15 absent a COMP360 Phase 3 topline or M&A announcement.

COMPASS Pathways (ticker: CMPS) is a company developing a synthetic psilocybin drug called COMP360 for depression. Without a major announcement — like results from their large Phase 3 trial (the final and most rigorous type of drug study) or news of a merger or acquisition — the stock price is expected to stay within about 12% of $11.39 through September 15, 2026. The veteran pilot study isn't significant enough to move investors.

No near-term binary catalyst on the calendar; the pilot paper is non-material. Volume stays thin until de-risking event.